Published in Gastroenterology on October 01, 2002
Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol (2007) 1.82
UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut (2015) 1.20
Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol (2013) 1.03
In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension. J Magn Reson Imaging (2012) 1.02
Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am (2010) 0.92
Management of portal hypertension. Postgrad Med J (2004) 0.90
Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci (2005) 0.87
Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol (2011) 0.84
Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc (2012) 0.83
Evolution of endoscopic therapy for esophageal varices. Surg Endosc (2006) 0.82
Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis. World J Gastroenterol (2009) 0.80
Impaired regulation of portal venous flow in response to a meal challenge as quantified by 4D flow MRI. J Magn Reson Imaging (2015) 0.79
Prevention and management of gastroesophageal varices in cirrhosis. Int J Hepatol (2012) 0.78
Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding. World J Gastroenterol (2012) 0.77
Current Management of Esophageal Varices. Curr Treat Options Gastroenterol (2003) 0.76
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? Clin Mol Hepatol (2012) 0.76
Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? Gastroenterology (2002) 0.76
The benefits of using Sentinel WebDashboard in medicine: IT solution for monitoring and treatment of patient with liver cirrhosis. J Med Life (2014) 0.75
Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol (2013) 0.75
Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial. World J Gastroenterol (2008) 0.75
Therapeutic potential of targeting the renin angiotensin system in portal hypertension. World J Gastrointest Pathophysiol (2013) 0.75
Long-term outcomes of endoscopic variceal ligation to prevent rebleeding in children with esophageal varices. J Korean Med Sci (2013) 0.75
Portal hypertension--old problem, new therapeutic solutions. Wien Med Wochenschr (2006) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet (2000) 4.67
Carcinoid tumour. Lancet (1998) 4.52
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther (2014) 3.98
Mental health and ethnicity: an Irish dimension. Br J Psychiatry (1998) 3.60
Staging system for clinical AIDS patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Lancet (1995) 2.90
Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev (2007) 2.75
The tRNA genes punctuate the reading of genetic information in human mitochondrial DNA. Cell (1980) 2.53
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol (2010) 2.50
Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J (1995) 2.39
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 2.35
The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant (2012) 2.29
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
Coagulation and fibrosis in chronic liver disease. Gut (2008) 2.22
Systematic review and meta-analysis of intraoperative versus preoperative endoscopic sphincterotomy in patients with gallbladder and suspected common bile duct stones. Br J Surg (2011) 2.13
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther (2006) 2.00
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 1.98
"Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology (1998) 1.95
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol (2002) 1.92
Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med (1991) 1.91
An appraisal of the histopathological assessment of liver fibrosis. Gut (2006) 1.87
Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection. BMJ (1994) 1.87
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther (2005) 1.86
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS (2001) 1.86
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol (1999) 1.76
Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet (2000) 1.75
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology (1999) 1.74
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology (1993) 1.69
Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS (1997) 1.68
Frequency of inherited bleeding disorders in women with menorrhagia. Lancet (1998) 1.66
Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med (1994) 1.65
Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (1996) 1.64
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut (1998) 1.63
Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev (2006) 1.63
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost (2010) 1.62
Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut (2006) 1.61
Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol (1999) 1.60
Nutrition and survival in patients with liver cirrhosis. Nutrition (2001) 1.60
Review article: portal vein thrombosis -- new insights into aetiology and management. Aliment Pharmacol Ther (2005) 1.59
Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1998) 1.57
Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther (2013) 1.56
Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med (2001) 1.55
Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition (1997) 1.54
Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant (2009) 1.52
Serum/ascites albumin gradient: its value as a rational approach to the differential diagnosis of ascites. Scand J Gastroenterol (1996) 1.48
The incubation period of AIDS. AIDS (1997) 1.47
Diurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol (1993) 1.47
Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant (2006) 1.47
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.46
Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. Hepatology (1996) 1.46
Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther (2007) 1.45
Portal hypertensive gastropathy: reproducibility of a classification, prevalence of elementary lesions, sensitivity and specificity in the diagnosis of cirrhosis of the liver. A NIEC multicentre study. New Italian Endoscopic Club. Ital J Gastroenterol Hepatol (1997) 1.45
Fractionation of mitochondrial RNA from HeLa cells by high-resolution electrophoresis under strongly denaturing conditions. J Mol Biol (1978) 1.44
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol (2005) 1.44
Viral burden in HIV infection. Nature (1994) 1.43
Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. Am J Transplant (2013) 1.40
CD8+ T cell counts up to 10 years from seroconversion. J Acquir Immune Defic Syndr (1993) 1.40
Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br J Radiol (2004) 1.40
Infection, coagulation, and variceal bleeding in cirrhosis. Gut (2005) 1.39
Staple-line erosion: a common source of recurrent bleeding following stapled oesophageal transection. Br J Surg (1991) 1.39
Hypophosphatemia and renal tubular dysfunction in alcoholics. Are they related to liver function impairment? Gastroenterology (1991) 1.39
The European-Australian Collaborative Group Study 017 of zidovudine versus placebo. AIDS (1994) 1.38
Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clin Radiol (1998) 1.38
LeVeen shunt with wandering tip. Lancet (1991) 1.36
Idiopathic acute fatty liver of pregnancy in 12 patients. Q J Med (1982) 1.36
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis (2004) 1.35
Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther (2009) 1.35
Assessing the impact of highly active antiretroviral therapy on AIDS and death. AIDS (1999) 1.30
Controversies in the management of bleeding esophageal varices (1) N Engl J Med (1989) 1.30
Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology (1999) 1.29
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis (2008) 1.26
Reduced bone mineral density in HIV-positive individuals. AIDS (2001) 1.26
The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS (1999) 1.26
Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology (1999) 1.25
Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant (2007) 1.25
Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol (1996) 1.25
Endoscopic extraction of bile duct stones: management related to stone size. Gut (1993) 1.24
Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis (1999) 1.23
Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. J Acquir Immune Defic Syndr (1999) 1.23
Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia (1999) 1.23
Bacteriuria and primary biliary cirrhosis. Gut (1984) 1.20
Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant (2012) 1.19
Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis (2002) 1.18
Donor-specific bone marrow infusion after orthotopic liver transplantation. Lancet (1994) 1.18
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer (2013) 1.17